12/15
07:05 am
abp
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]
Low
Report
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]
12/15
07:00 am
abp
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
High
Report
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
12/9
07:00 am
abp
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Medium
Report
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
11/26
02:00 pm
abp
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/8
01:13 am
abp
Medium
Report
11/4
09:15 am
abp
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
High
Report
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
10/21
11:00 am
abp
Abpro (NASDAQ:ABP) had its "hold" rating reaffirmed by analysts at Maxim Group.
Low
Report
Abpro (NASDAQ:ABP) had its "hold" rating reaffirmed by analysts at Maxim Group.
10/3
02:37 pm
abp
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.